CAL02
Phase 2Small molecule
CAL02 is one of 9 small molecule programs targeting Bacterial Pneumonia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Bacterial Pneumonia
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Ketek
SanofiApproved
Levaquin
WWim Janssens
Approved
Tygacil
PPrism Pharmaceuticals
Approved
Amikin
IInsmed Incorporated
Approved
Avycaz
PPhiladelphia Eye Associates
Approved
Teflaro
AbbVieApproved
Polymyxin B
MMahidol University
Phase 3
CAL02
EEagle Pharmaceuticals, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAL02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEagle Pharmaceuticals, Inc.